PharVision Advisers’s Cricut CRCT Stock Holding History

PharVision Advisers’s Portfolio CRCT Stock Details CRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,004	Closed	-$101K	–	740
2025 Q3	$101K	Buy	+16,004	New	+$93.7K	0.06%	623

Other funds holding CRCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Algert Global San Francisco, California $6.65B AUM 53.68% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PharVision Advisers's CRCT Position: Q4 2025 in Review

PharVision Advisers sold out of Cricut (CRCT) in Q4 2025, closing a stake of 16,004 shares — an estimated $101K sold.

PharVision Advisers first reported a position in CRCT in Q3 2025 and held it in 1 quarter. The position peaked at $101K in Q3 2025. 157 funds tracked by Wall St. Rank hold CRCT as of Q4 2025.

PharVision Advisers reported no remaining Cricut position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 16,004 Cricut shares in Q4 2025, an estimated $101K.
PharVision Advisers first reported a position in Cricut in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Cricut position peaked at $101K in Q3 2025.
157 funds tracked by Wall St. Rank held Cricut as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.